alanine and rabeprazole

alanine has been researched along with rabeprazole in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Azuma, T; Fujiwara, S; Itoh, T; Kawakami, F; Kutsumi, H; Morita, Y; Toyonaga, T; Yoshida, M1
Bello, E; Berndt, A; Camboni, G; Cavalletti, E; Colella, G; D'Incalci, M; Damia, G; Forestieri, D; Giavazzi, R; Licandro, SA; Richter, P; Taraboletti, G; Zucchetti, M1
Akahoshi, K; Akiho, H; Aso, A; Harada, N; Iboshi, Y; Ihara, E; Iwasa, T; Nakamura, K; Nakamura, N; Ochiai, T; Ogino, H; Takayanagi, R1

Trials

2 trial(s) available for alanine and rabeprazole

ArticleYear
A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection.
    Journal of gastroenterology, 2011, Volume: 46, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Alanine; Anti-Ulcer Agents; Disease Progression; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; Gastritis, Atrophic; Gastroscopy; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Quinolones; Rabeprazole; Severity of Illness Index; Stomach Neoplasms; Stomach Ulcer

2011
Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy.
    Gut and liver, 2016, Nov-15, Volume: 10, Issue:6

    Topics: Adenoma; Aged; Alanine; Anti-Ulcer Agents; Drug Therapy, Combination; Endoscopic Mucosal Resection; Female; Gastric Mucosa; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Proton Pump Inhibitors; Quinolones; Rabeprazole; Stomach Neoplasms; Stomach Ulcer; Treatment Outcome

2016

Other Studies

1 other study(ies) available for alanine and rabeprazole

ArticleYear
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:2

    Topics: Alanine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Female; Humans; Indoles; Mice; Mice, Nude; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Rabeprazole; Random Allocation; Sunitinib; Triazines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2013